NDA 022088 · Pf Prism Cv
Torisel
Temsirolimus · Intravenous
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Mar 23, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
May 30, 2007
Approved uses
4
Original approval plus efficacy supplements
Registered trials
938
98 Phase 3, 68 recruiting
FAERS reports
4,506
3,854 serious, 969 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 26, 2025.
TORISEL is indicated for the treatment of advanced renal cell carcinoma. TORISEL ® is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma. ( 1 )
Mechanism: Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds to an intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTOR that controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treated tumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomal protein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In in vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTOR and resulted in reduced levels of the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 30, 2012 Supplement 14 · Efficacy LabelPediatric Written RequestPediatric Amendment 1
- Jul 9, 2010 Supplement 8 · Efficacy LetterLabel
- Apr 26, 2010 Supplement 6 · Efficacy LetterLabel
- May 30, 2007 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewPediatric Medical ReviewPediatric Clinical Pharmacology Review
1 products under this application
- TORISEL · TEMSIROLIMUS 25MG/ML (25MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Temsirolimus" as an intervention, any sponsor and status, largest first.
- Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)Pivotal-lookingRecruiting
Gan LijunAcademic, hospital or other
NCT07587099 · 2,170 participants (planned) · Start May 4, 2026 · Primary completion Dec 31, 2029
Drug: Single antiplatelet therapy (SAPT); Dual antiplatelet therapy (DAPT) · For: Coronary Heart Disease (CHD)
Sites: Beijing, China; Haikou, China; Harbin, China · 14 sites in all
- Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS SystemPivotal-lookingNot yet recruiting
Lepu Medical Technology (Beijing) Co., Ltd.Industry
NCT04995159 · 2,150 participants (planned) · Start Sep 2021 · Primary completion Jan 2026
Drug: Single anti-platelet therapy; Dual anti-platelet therapy · For: Coronary Heart Disease
Sites: Bengbu, China; Hefei, China; Wuhu, China · 114 sites in all
National Cancer Institute (NCI)NIH
NCT03155620 · 1,377 participants · Start Jul 31, 2017 · Primary completion Mar 31, 2025
Drug: Ensartinib; Erdafitinib and 11 more · For: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma and 42 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Mesa, Arizona · 172 sites in all
- Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast CancerPivotal-lookingTerminated
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00083993 · 1,236 participants · Start May 2004 · Primary completion Oct 2006
Drug: Temsirolimus (CCI-779) for 34 months; Letrozole for 34 months · For: Breast Neoplasms; Neoplasm Metastasis
Sites: Hoover, Alabama; Huntsville, Alabama; Tucson, Arizona · 129 sites in all
- Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney TransplantationPivotal-lookingCompleted
Hospital do Rim e HipertensãoAcademic, hospital or other
NCT03468478 · 1,209 participants · Start Jun 18, 2017 · Primary completion Mar 18, 2021
Drug: Sirolimus; Everolimus and 1 more · For: Kidney Transplant Infection
Sites: São Paulo, Brazil
- A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.Pivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT01363752 · 853 participants · Start Mar 8, 2011 · Primary completion Sep 18, 2013
Drug: Advagraf; Mycophenolate Mofetil and 2 more · For: Kidney Transplantation
Sites: New Lambton, Australia; Perth, Australia; Innsbruck, Austria · 58 sites in all
- Campath, Calcineurin Inhibitor Reduction and Chronic Allograft NephropathyPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT01120028 · 852 participants · Start Sep 2010 · Primary completion Feb 2014
Drug: Alemtuzumab; Basiliximab and 2 more · For: Kidney Transplantation
Sites: Oxford, United Kingdom; Birmingham, United Kingdom; Cambridge, United Kingdom · 20 sites in all
- Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma SubjectsPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00631371 · 791 participants · Start Apr 2008 · Primary completion Apr 2012
Drug: Bevacizumab; Temsirolimus and 2 more · For: Renal Cell Carcinoma
Sites: Little Rock, Arkansas; Chula Vista, California; La Mesa, California · 172 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- disease progression479
- death287
- dyspnoea216
- fatigue206
- pneumonia190
- diarrhoea189
- nausea189
- anaemia188
- pyrexia179
- vomiting176
- thrombocytopenia164
- dehydration162
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 4 |
| 2007 | 132 |
| 2008 | 422 |
| 2009 | 352 |
| 2010 | 523 |
| 2011 | 426 |
| 2012 | 538 |
| 2013 | 399 |
| 2014 | 279 |
| 2015 | 328 |
| 2016 | 247 |
| 2017 | 153 |
| 2018 | 132 |
| 2019 | 119 |
| 2020 | 106 |
| 2021 | 79 |
| 2022 | 138 |
| 2023 | 60 |
| 2024 | 44 |
| 2025 | 16 |
| 2026 | 9 |
Recalls
2 FDA enforcement reports for this application.
Oct 10, 2014 · Class III · Terminated
Crystallization: Impurities in a raw material used to manufacture the diluent can cause the formation of crystals in the diluent vials after cold storage. The TORISEL vials are not affected by this issue.
Nov 26, 2012 · Class III · Terminated
Lack of Assurance of Sterility; potential that a low level of endotoxins may be present in the diluent vials.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group.
Gupta AA, Xue W, Harrison DJ, et al. · Lancet Oncol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
Aghajanian C, Filiaci V, Dizon DS, et al. · Gynecol Oncol 2018 · Clinical Trial, Phase II, Multicenter Study
- Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R, Naranjo A, Van Ryn C, et al. · Lancet Oncol 2017 · Clinical Trial, Phase II, Multicenter Study
- Temsirolimus Adventitial Delivery to Improve ANGiographic Outcomes Below the Knee.
Cawich I, Armstrong EJ, George JC, et al. · J Endovasc Ther 2024 · Multicenter Study, Randomized Controlled Trial
- Phase II Trial of Bevacizumab Monotherapy in Pancreatic Neuroendocrine Tumors.
Zhu M, Costello BA, Yin J, et al. · Pancreas 2021 · Clinical Trial, Phase II, Multicenter Study
- Targeted therapy for metastatic renal cell carcinoma.
Motzer RJ, Bukowski RM · J Clin Oncol 2006 · Systematic Review
Sponsor: Pf Prism Cv
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.